Stockreport

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

TScan Therapeutics, Inc.  (TCRX) 
PDF WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell [Read more]